The European Investment Bank and Angelini Ventures have signed an agreement to provide €150 million in financing for European biotechnology and digital health startups. Each party will invest €75 million over the next six years.
This is the first agreement the EIB has signed with a corporate venture capital in the healthcare sector. Under the agreement, the EIB and Angelini Ventures plan to co-invest in seven to ten European startups developing solutions in biotechnology, medical technology, and digital health.
“Investing in biotechnology and digital health is vital, as it accelerates research, improves the quality of care, and supports the growth of companies able to bring cutting-edge solutions to market,” said EIB Vice-President Gelsomina Vigliotti.
The initiative is aligned with TechEU, the EIB Group’s investment programme to strengthen innovation and technological leadership in Europe. Via TechEU, the EIB Group aims to invest €70 billion in equity, quasi-equity, loans, and guarantees over the three-year period from 2025 to 2027, with the goal of mobilizing €250 billion of investment in the real economy.
Angelini Ventures was founded in 2022 with €300 million from Angelini Industries. The company has already invested €125 million in 22 startups.
“This important agreement with the EIB enables us to bring our group’s commitment to innovation through venture capital to a European strategic context,” said Angelini Industries CEO Sergio Marullo di Condojanni. “Being chosen by the EIB for an ambitious project aiming to consolidate Europe’s role in innovation and health is an opportunity to work towards the common goal of turning researchers’ excellent ideas into products and services with a positive impact on people’s lives and the economic development of European countries.”
As a first step, Angelini Ventures and the EIB intend to co-invest in the second financing round of Adcytherix, a French biopharmaceutical company that develops Antibody-Drug Conjugates. The investment agreement is being finalized. The first round closed in October 2025 and was led by Bpifrance, co-led by Kurma Partners, Andera Partners, and Angelini Ventures.
“The agreement with the EIB is a key step in strengthening our international presence and global vision,” said Angelini Ventures CEO Paolo Di Giorgio. “This development path is essential to accelerating market access for talent and innovative projects, facilitating strategic partnerships in health and offering scaling opportunities for investments and partners.”
Angelini Ventures is based in Rome and has a global team of 17 professionals working in nine cities. Angelini Industries is an Italian industrial group founded in 1919 that operates in health, industrial technology, and consumer goods sectors, with around 5,600 employees in 21 countries and annual revenues of €1.6 billion.
